Shots:
- Health Canada has approved Portela for alleviating osteoarthritis pain in cats. The company plans to launch Portela commercially in Canada and the EU in 2026
- In a nine-month European trial, Portela eased OA pain and was well tolerated, including in cats with IRIS stage 1–3 kidney disease. Approved in the EU
- Portela is a long-acting anti-NGF mAb therapy for cats, designed to deliver up to 3mos. of osteoarthritis pain relief with a single injection
Ref: Zoetis | Image: Zoetis | Press Release
Related News: Zoetis’ Lenivia (Izenivetmab) Receives the EC Approval for Osteoarthritis Pain Relief in Dogs
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
